Anything is better than chemo.
By now, most plandemic skeptics are aware of the fact that ivermectin, a cheap, off-patent anti-malaria drug, is a powerful remedy for the Wuhan coronavirus (Covid-19), hence why the government does not want people to have it. But did you also know that ivermectin treats cancer? ~ DrLeonardColdwell.com More below.
Dr. Bryan Ardis and Dr. Ryan Cole on Effectiveness of Ivermectin for Coronavirus at 9 minutes and 25 minutes. Dr. Mercola and Dr. Pierre Kory on Ivermectin.
They cannot have generic, off-patent drugs become standard of care. It obliterates the [bigPharma] market for their pricing and pills...In the history of pharma, I don't think any single medicine threatened as many markets... ~ Dr. Pierre Kory
The War on Ivermectin: The outcome could have been much different - and many lives saved - if Big Pharma hadn't been so successful at suppressing this generic pharmaceutical that was found to work against COVID-19. ~ Dr. Pierre Kory and Dr. Mercola
Front Line Alliance I-Prevent Protocol Dosages: Ivermectin is an effective treatment for covid, cancer and also a stand-alone weekly preventative measure with less side-effects than anti-biotics and does not damage the gut microbiome. More Ivermectin Protocol Details.
Dosage is calculated by body weight in kilograms. 1 American lb (pound) = 0.45 kg (kilograms). For those sensitive to medication, start with a half dose.
Maintenance Dose for Chronic Prevention is 0.2mg Ivermectin per kilogram of body weight. FLCCCA Front Line Covid Critical Care Alliance:
0.2 mg/kg. Start with one dose, take second dose 48 hours later, then 1 dose every 7 days (weekly). Those at high risk of contracting COVID-19 can consider dosing twice a week.
Standard Dose for Acute Prevention is 0.4mg Ivermectin per kilogram of body weight. Take once per day with fatty food for 2-5 days. Dr. Ryan Cole at www.RcoleMD.com
Dose Calculation Example:
Step 1.) Convert weight in pounds to kilograms, 100 lbs x 0.45 = 45 kg.
Step 2.) Multiply weight in kilograms by 0.4, for example, 45 kg x 0.4 = 18 mg Ivermectin.
At least nine different peer-reviewed studies demonstrate how safe and effective ivermectin wards off the Big C, threatening the multi-billion dollar cancer industry. There are two industries, in other words, that ivermectin threatens: the covid industry and the cancer industry. ~ DrLeonardColdwell.com
Ivermectin in Oncology - The Science. In laboratory, Ivermectin has been shown to be able to kill cancer cells of many types, such as Breast Cancer (Ref.1, Ref.2, Ref.3)
Ovarian Cancer (Ref.1, Ref.2), Prostate Cancer, Colorectal Cancer, Brain Cancer (Ref.1, Ref.2, Ref.3, Ref.4)
Renal Cancer, Leukemia, AML, Hepatocellular carcinoma (Ref.), Lung Cancer (Ref.1, Ref.2) and many others. ~ CancerTreatmentsResearch.com
Ivermectin's Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity. Sabine Hazan:
...Decreased Bifidobacterium levels are observed in COVID-19 susceptibility states, including old age, autoimmune disorder, and obesity. We hypothesize that Ivermectin, as a by-product of Streptomyces fermentation, is capable of feeding Bifidobacterium, thereby possibly preventing against COVID-19 susceptibilities. Moreover, Bifidobacterium may be capable of boosting natural immunity, offering more direct COVID-19 protection. These data concord with our study, as well as others, that show Ivermectin protects against COVID-19.
Ivermectin is an old, common, and classic anti-parasite drug, which has been found to have a broad-spectrum anti-cancer effect on multiple human cancers. This chapter will focus on the anti-cancer effects of ivermectin on ovarian cancer. First, ivermectin was found to suppress cell proliferation and growth, block cell cycle progression, and promote cell apoptosis in ovarian cancer.
Ivermectin, as an old anti-parasite drug, can suppress almost completely the growth of various human cancers, including ovarian cancer (OC).
It has been used by millions of people around the world exhibiting a wide margin of clinical safety. In this review, we summarize the in vitro and in vivo evidences demonstrating that ivermectin exerts antitumor effects in different types of cancer. Ivermectin interacts with several targets including the multidrug resistance protein (MDR), the Akt/mTOR and WNT-TCF pathways, the purinergic receptors, PAK-1 protein, certain cancer-related epigenetic deregulators such as SIN3A and SIN3B, RNA helicase, chloride channel receptors and preferentially target cancer stem-cell like population.
Importantly, the in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients. Thus, existing information on ivermectin could allow its rapid move into clinical trials for cancer patients.
In our current study, we demonstrated that ivermectin displayed preclinical activity against hematologic malignancies in vitro and delayed tumor growth in vivo at concentrations that appear pharmacologically achievable. Mechanistically, ivermectin induced chloride influx, membrane hyperpolarization, and generated reactive oxygen species (ROS). Furthermore, ivermectin synergized with cytarabine and daunorubicin. Thus, given its prior safety and toxicity testing, ivermectin could be rapidly advanced into clinical trial for patients with leukemia.
In human ovarian cancer and NF2 tumor cell lines, high-dose ivermectin inactivates protein kinase PAK1 and blocks PAK1-dependent growth. PAK proteins are essential for cytoskeletal reorganization and nuclear signaling, PAK1 being implicated in tumor genesis while inhibiting PAK1 signals induces tumor cell apoptosis (cell death).
PAK1 is essential for the growth of more than 70% of all human cancers, including breast, prostate, pancreatic, colon, gastric, lung, cervical and thyroid cancers, as well as hepatoma, glioma, melanoma, multiple myeloma and for neurofibromatosis tumors.110
Oesophageal squamous cell carcinoma (ESCC), the most common form of oesophageal malignancies in the Asia-Pacific region, remains a major clinical challenge. In this study, we found that ivermectin, an effective antiparasitic drug that has been approved for patients to orally treat onchocerciasis for over 30 years, displayed potent antitumour activity against ESCC cells in vitro and in nude mice. We demonstrated that ivermectin significantly inhibited cell viability and colony formation, and induced apoptosis through a mitochondrial-dependent manner in ESCC cells. Ivermectin also abrogated ESCC cell migration, invasion, as well as the protein levels of MMP-2 and MMP-9. Mechanistically, ivermectin strongly inhibited the expression of PAK1; by further gain- and loss-of-function experiments, we confirmed that PAK1 played a crucial role in ivermectin-mediated inhibitory effects on ESCC cells. In addition, the data indicated that ivermectin promoted PAK1 degradation through the proteasome-dependent pathway. Additionally, ivermectin synergized with chemotherapeutic drugs including cisplatin and 5-fluorouracil to induce apoptosis of ESCC cells. Interestingly, the in vivo experiments also confirmed that ivermectin effectively suppressed tumour growth and lung metastasis of ESCC. Collectively, these results indicate that ivermectin exerts a potent antitumour activity against ESCC and is a promising therapeutic candidate drug for ESCC patients, even those carrying metastasis.
Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses.
Ivermectin has powerful antitumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin through PAK1 kinase. On the other hand, ivermectin promotes programmed cancer cell death, including apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and autophagy is mutually regulated. Interestingly, ivermectin can also inhibit tumor stem cells and reverse multidrug resistance and exerts the optimal effect when used in combination with other chemotherapy drugs.
Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth.... The results demonstrated that ivermectin dose-dependently inhibited colorectal cancer SW480 and SW1116 cell growth, followed by promoting cell apoptosis and increasing Caspase-3/7 activity....Overall, ivermectin suppressed cell proliferation by promoting ROS-mediated mitochondrial apoptosis pathway and inducing S phase arrest in CRC cells, suggesting that ivermectin might be a new potential anticancer drug therapy for human colorectal cancer and other cancers.